



NDA 20863/S-23

SUPPLEMENT APPROVAL

Otsuka Pharmaceutical Development and Commercialization, Inc
Attention: Craig Ostroff, PharmD
Senior Director, Global Regulatory Affairs
508 Carnegie Center, 4th Floor, 4201b
Princeton, NJ 08540

Dear Dr. Ostroff:

Please refer to your Supplemental New Drug Application (sNDA) dated August 29, 2014, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Pletal (cilostazol) tablets.

We acknowledge receipt of your amendments dated March 20, June 5, and July 24, 2015

This "Prior Approval" supplemental new drug application provides for revisions to comply with the formatting requirements of 21 CFR 201.56(d). Content changes were also made in section 4, Contraindications. Editorial and organizational changes were made throughout the label.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call:

Michael Monteleone, MS, RAC
Associate Director for Labeling
(301) 796-1952

Sincerely,

{See appended electronic signature page}

Norman Stockbridge, MD, PhD
Director
Division of Cardiovascular & Renal Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE:
Agreed-Upon Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

NORMAN L STOCKBRIDGE
07/30/2015